These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 16536908

  • 1. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
    Lattmann E, Singh H, Boonprakob Y, Lattmann P, Sattayasai J.
    J Pharm Pharmacol; 2006 Mar; 58(3):393-401. PubMed ID: 16536908
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and evaluation of N-(5-methyl-3-oxo-1,2- diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas as cholecystokinin antagonists.
    Lattmann E, Sattayasai J, Boonprakob Y, Lattmann P, Singh H.
    Arzneimittelforschung; 2005 Mar; 55(5):251-8. PubMed ID: 15960423
    [Abstract] [Full Text] [Related]

  • 3. Cholecystokinin antagonists (part 1): Antinociceptive, anxiolytic and antidepressant effects of N-(5-methyl-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas and carboxamides.
    Lattmann E, Sattayasai J, Boonprakob Y, Singh H, Lattmann P, Dunn S.
    Drug Discov Ther; 2008 Jun; 2(3):156-67. PubMed ID: 22504568
    [Abstract] [Full Text] [Related]

  • 4. Synthesis of substituted 3-anilino-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-ones and their evaluation as cholecystokinin-ligands.
    Offel M, Lattmann P, Singh H, Billington DC, Bunprakob Y, Sattayasai J, Lattmann E.
    Arch Pharm (Weinheim); 2006 Apr; 339(4):163-73. PubMed ID: 16572480
    [Abstract] [Full Text] [Related]

  • 5. 3,5-Diphenyl-1H-pyrazole derivatives. IV--N,N-disubstituted 3-(3,5-diphenyl-1H-pyrazol-1-yl)propanamides and 3-(3,5-diphenyl-1H-pyrazol-1-yl)propanamines with sedative, platelet antiaggregating and local anesthetic activities.
    Bondavalli F, Bruno O, Ranise A, Schenone P, Losasso C, Donnoli D, Stella L, Marmo E.
    Farmaco; 1990 Feb; 45(2):137-46. PubMed ID: 2133991
    [Abstract] [Full Text] [Related]

  • 6. Part 2. Long term in vivo/in vitro evaluation of the Cholecystokinin antagonists: N-(5-methyl-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylurea MPP and carboxamide MPM.
    Lattmann E, Boonprakob Y, Sattayasai J.
    Drug Discov Ther; 2008 Dec; 2(6):344-52. PubMed ID: 22504744
    [Abstract] [Full Text] [Related]

  • 7. Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides.
    Borza I, Bozó E, Barta-Szalai G, Kiss C, Tárkányi G, Demeter A, Gáti T, Háda V, Kolok S, Gere A, Fodor L, Nagy J, Galgóczy K, Magdó I, Agai B, Fetter J, Bertha F, Keserü GM, Horváth C, Farkas S, Greiner I, Domány G.
    J Med Chem; 2007 Mar 08; 50(5):901-14. PubMed ID: 17290978
    [Abstract] [Full Text] [Related]

  • 8. In vivo evaluation of substituted 3-amino-1,4-benzodiazepines as anti-depressant, anxiolytic and anti-nociceptive agents.
    Lattmann E, Lattmann P, Boonprakob Y, Airarat W, Singh H, Offel M, Sattayasai J.
    Arzneimittelforschung; 2009 Mar 08; 59(2):61-71. PubMed ID: 19338136
    [Abstract] [Full Text] [Related]

  • 9. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
    Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP.
    J Pharmacol Exp Ther; 2007 Nov 08; 323(2):562-9. PubMed ID: 17684117
    [Abstract] [Full Text] [Related]

  • 10. Facile synthesis of fused pyrazolo[1,5-a]pyrimidinepyrazolo [1,5-a]triazines and N-sulphonamidopyrazoles as antiinflammatory.
    Fathalla OA, Zaki ME, Swelam SA, Nofal SM, el-Eraky WI.
    Acta Pol Pharm; 2003 Nov 08; 60(1):51-60. PubMed ID: 12848368
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
    Silvestri R, Ligresti A, La Regina G, Piscitelli F, Gatti V, Lavecchia A, Brizzi A, Pasquini S, Allarà M, Fantini N, Carai MA, Bigogno C, Rozio MG, Sinisi R, Novellino E, Colombo G, Di Marzo V, Dondio G, Corelli F.
    Eur J Med Chem; 2010 Dec 08; 45(12):5878-86. PubMed ID: 20943290
    [Abstract] [Full Text] [Related]

  • 12. 3,5-Diphenyl-1H-pyrazole derivatives. VIII. N-substituted 3-(4-hydroxy-3,5-diphenyl-1H-pyrazol-1-yl)-propanamides, -propanamines and 2-(4-hydroxy-3,5-diphenyl-1H-pyrazol-1-yl)ethanamines with platelet antiaggregating, hypotensive, antiarrhythmic and other activities.
    Bruno O, Bondavalli F, Ranise A, Schenone P, Cenicola ML, Donnoli D, Filippelli W, Losasso C, Costantino M, Marmo E.
    Farmaco; 1991 Mar 08; 46(3):477-99. PubMed ID: 1892504
    [Abstract] [Full Text] [Related]

  • 13. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.
    Shimamura K, Kitazawa H, Miyamoto Y, Kanesaka M, Nagumo A, Yoshimoto R, Aragane K, Morita N, Ohe T, Takahashi T, Nagase T, Sato N, Tokita S.
    J Pharmacol Exp Ther; 2009 Jul 08; 330(1):249-56. PubMed ID: 19359527
    [Abstract] [Full Text] [Related]

  • 14. Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis.
    Hopkins CR, O'neil SV, Laufersweiler MC, Wang Y, Pokross M, Mekel M, Evdokimov A, Walter R, Kontoyianni M, Petrey ME, Sabatakos G, Roesgen JT, Richardson E, Demuth TP.
    Bioorg Med Chem Lett; 2006 Nov 01; 16(21):5659-63. PubMed ID: 16919947
    [Abstract] [Full Text] [Related]

  • 15. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, Arban R, Poffe A, Melotto S, Hagan JJ, Price GW.
    Neuropharmacology; 2006 Jun 01; 50(8):975-83. PubMed ID: 16581092
    [Abstract] [Full Text] [Related]

  • 16. 3,5-Diphenyl-1H-pyrazole derivatives. IX. 2-substituted 4-phenyl-5-(3,5-diphenyl-1H-pyrazol-1-yl) pyrimidines with platelet antiaggregating and other activities.
    Bondavalli F, Bruno O, Ranise A, Schenone P, D'Amico M, Parrillo C, Filippelli W, Rossi F.
    Farmaco; 1992 Feb 01; 47(2):171-90. PubMed ID: 1510792
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological activity of a series of aryl tropanyl esters and amides chemically related to 1H-indole-3-carboxylic acid endo 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester. Development of a 5-HT4 agonist endowed with potent antinociceptive activity.
    Romanelli MN, Ghelardini C, Dei S, Matucci R, Mori F, Scapecchi S, Teodori E, Bartolini A, Galli A, Giotti A.
    Arzneimittelforschung; 1993 Aug 01; 43(8):913-8. PubMed ID: 8216452
    [Abstract] [Full Text] [Related]

  • 18. Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists.
    Borza I, Kolok S, Galgóczy K, Gere A, Horváth C, Farkas S, Greiner I, Domány G.
    Bioorg Med Chem Lett; 2007 Jan 15; 17(2):406-9. PubMed ID: 17074483
    [Abstract] [Full Text] [Related]

  • 19. Studies on the synthesis and antidepressant activity of some 1-thiocarbamoyl-3,5-diphenyl-2-pyrazolines.
    Bilgin AA, Palaska E, Sunal R.
    Arzneimittelforschung; 1993 Oct 15; 43(10):1041-4. PubMed ID: 8267665
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and antidepressant-like profile of novel 1-aryl-3-[(4-benzyl)piperidine-1-yl]propane derivatives.
    Köksal M, Bilge SS.
    Arch Pharm (Weinheim); 2007 Jun 15; 340(6):299-303. PubMed ID: 17562562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.